Palonosetron
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Palonosetron: From Chemotherapy-Related Nausea and Vomiting to Migraine Disorder
One-Sentence Summary
Palonosetron is a 5-HT3 receptor antagonist, a drug class used to prevent nausea and vomiting. The TxGNN model predicts it may be effective for migraine disorder, but this is a model prediction only, with 0 clinical trials and 1 publication (a case report describing palonosetron causing migraine-type headache), so the evidence points the opposite way from a benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report (palonosetron is generally known as an antiemetic) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 14 (all cancelled; 11 ANDAs and 3 NDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, palonosetron is a 5-HT3 receptor antagonist, and it is used as an antiemetic. Mechanistically, 5-HT3 antagonism has a plausible but unproven link to migraine, through serotonergic signalling and nausea/vomiting pathways, since nausea is a prominent migraine symptom.
The high TxGNN score (0.997) reflects proximity in a knowledge graph, not demonstrated efficacy. The only retrieved publication reports palonosetron-induced migraine-type headache, an adverse-event signal that runs counter to a therapeutic benefit. No clinical trials were found.
The other predictions are weaker still:
- Migraine with brainstem aura (99.67%): likely driven by graph proximity to the general migraine node, with no specific evidence.
- Migraine with or without aura, susceptibility to (99.44%): a genetic-susceptibility label rather than a treatable condition.
- Atrophoderma vermiculata (99.13%) and ulerythema ophryogenesis (99.07%): no identifiable mechanistic rationale; these two predictions are probably correlated through shared graph neighbours.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21132477 | 2011 | Case report | Canadian Journal of Anaesthesia | Reports migraine-type headache induced by palonosetron, an adverse-event signal rather than evidence of benefit |
A 2026 review of antiemetic-associated QT prolongation (PMID 42748473, European Heart Journal – Cardiovascular Pharmacotherapy) was retrieved for a related migraine-susceptibility prediction. It is a safety review, not evidence of efficacy in migraine, and is therefore not listed above.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA215861 | Palonosetron Hydrochloride (Meitheal) | Injection, solution | Not available (cancelled) |
| ANDA206916 | Palonosetron Hydrochloride (Baxter) | Injection | Not available (cancelled) |
| ANDA205648 | Palonosetron (Apotex) | Injection | Not available (cancelled) |
| NDA203050 | Posfrea (Avyxa Pharma) | Injection, solution | Not available (cancelled) |
| NDA021372 | Palonosetron Hydrochloride (Cipla) | Injection | Not available (cancelled) |
All 14 licenses in the data are cancelled, so there is no currently valid US marketed product. Only the 5 main authorizations are shown here. Only injectable forms are listed.
Cytotoxicity
Palonosetron is an antiemetic (supportive care) and not an antineoplastic agent, so no cytotoxicity profile is applicable.
Safety Considerations
- Drug Interactions: 100 interactions were identified in total. Examples classified as Major include:
- Opioids and analgesics: fentanyl, alfentanil, tramadol, dextromethorphan
- Triptans: almotriptan, sumatriptan
- QT-relevant or antiarrhythmic and psychotropic agents: amiodarone, amisulpride, amitriptyline, anagrelide
- Moderate examples include abiraterone, codeine, dihydrocodeine, famotidine, formoterol, adenosine, salbutamol, alfuzosin, propofol, and loperamide.
- Notable concerns for a migraine setting: the interactions with triptans (the standard acute migraine therapy) are Major and would need evaluation. A 2026 review also highlights QT prolongation as a class-level liability for antiemetics.
- Key warnings and contraindications: package insert warnings and contraindications were not available. Please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a graph-based score alone. The only publication suggests palonosetron may provoke migraine-type headache, and there are no clinical trials. The drug also has no currently valid US license, and Major interactions with triptans add practical barriers.
To proceed, the following is needed:
- Mechanism of action data and a reasoned link between 5-HT3 antagonism and migraine
- A systematic literature search on 5-HT3 antagonists in migraine, including the headache adverse-event signal
- Package insert warnings and contraindications for the safety screening
- Clarification of the regulatory and market status, since all licenses are cancelled
- Preclinical or early exploratory clinical data before any further consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.